Patent intelligence · US
US 12161607
Combination of cannabinoids in the treatment of leukemia
Combination of cannabinoids in the treatment of leukemia
Patent details — US 12161607
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2024
- Expiration
- Dec 5, 2044
- Applicant
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
- Claims
- 16
- CPC classes
- A61K, A61K31/05, A61K31/352, A61K31/475
Quick answer
US 12161607 (Combination of cannabinoids in the treatment of leukemia) is held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/05, A61K31/352, A61K31/475, A61K31/658, A61K31/7068
More from JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 12161607?
US 12161607 (Combination of cannabinoids in the treatment of leukemia) is held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12161607?
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 12161607 expire?
Our index shows an expiration date of Dec 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.